Ankyra Therapeutics
PrivateLast Round
Series B
Nov 12, 2021
Total Funding Raised
$50M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ankyra Therapeutics is a biotechnology company that develops anchored-drug conjugates to enhance the safety and effectiveness of cytokine immunotherapies for cancer patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ankyra Therapeutics Comparables
Compare Ankyra Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Xilio Therapeutics | 83% | |
| Bright Peak Therapeutics | 79% | |
| Synthekine | 79% |
Ankyra Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 12, 2021 | ||||
| Series A | May 4, 2020 |
Key People
Founding team and executive leadership
Ankyra Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GV | Series B |
| Fidelity Management & Research Company | Series B |
| Borealis Ventures | Series B |
| Polaris Partners | Series B, Series A |
| Sands Capital | Series B |
| Spring Mountain Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 41% MoM.
- Apr 16, 2026
Clinical presentations on novel IL-12 immunotherapy at AACR 2026.
Recent news
Latest coverage and updates
- is_developingSep 21, 2026
Ankyra Therapeutics, Inc. is developing ANK-101.
Ankyra Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ankyra Therapeutics's valuation, stock price, and market status.
Is Ankyra a public or private company?
Ankyra is a private company.
What is the current stock price of Ankyra?
Ankyra is a private company with no public stock price. No recent secondary market data is available.
How much is Ankyra worth (valuation)?
Valuation information for Ankyra is not publicly available.
Can I buy Ankyra stock?
Ankyra shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ankyra's last funding round?
Ankyra's most recent funding round was Series B on November 12, 2021.
Who are the main investors in Ankyra?
Key investors in Ankyra include Polaris Partners, Sands Capital, Spring Mountain Capital.
Will Ankyra IPO soon?
No public IPO plans have been announced for Ankyra.
How can I track Ankyra secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ankyra's secondary market activity and sign up for updates.